Safety and sustained efficacy of the farnesoid X receptor (FXR) agonist cilofexor over a 96-week open-label extension in patients with PSC.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association（2022）
摘要
gov identifier: NCT02943460.
更多查看译文
关键词
UDCA,cholestasis,farnesoid X receptor,large duct PSC,primary sclerosing cholangitis
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要